Siltuximab for Preventing Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge
Phase 2
40
about 6.5 years
18+
1 site in OH
What this study is about
This trial is testing if giving siltuximab during the reintroduction of immune checkpoint inhibitor (ICI) therapy can prevent severe immune-related adverse events (irAEs) in patients with advanced cancer. ICI therapy may cause severe irAEs that can affect many organs, potentially leading to stopping treatment early and progression. Siltuximab is a monoclonal antibody that may help reduce inflammation and prevent these severe irAEs during the rechallenge.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Quality-of-Life Assessment
- 2.Receive Anti-PD-L1 Monoclonal Antibody
- 3.Receive Anti-PD1 Monoclonal Antibody
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
siltuximab
injection (Injection)
Primary: Incidence of severe immune-related adverse event (irAE)
Secondary: Median progression-free survival, Overall response rate, Overall survival
biopsy, diagnostic, imaging